Quanticate Appoints President and Expands Services
Biometrics Company Quanticate Appoints Andrew MacGarvey to President of U.S. Operations Signaling Further Expansion of CRO Services
Cambridge, MA and London,UK–January 28, 2009 -Quanticate, a global biometrics clinical research organization (CRO) today announced that it has appointed Andrew MacGarvey as President of its U.S. operations headquartered in Cambridge, MA. The position indicates the company’s mission to further expand its clinical trial service capabilities with MacGarvey managing the company’s initiatives in support of existing and new U.S. clients. In addition, MacGarvey will continue to direct the company’s global sales efforts.
“The move to establishing a U.S. headquarters is in response to the terrific reception of our products by companies here in the States,” said MacGarvey. “We have been handling clinical trials for our U.S. customers here and overseas for some time. Our mission now is to grow the office and add more operational elements in line with our customers’ requirements.”
Prior to joining Quanticate, MacGarvey served as a Director at Datatrial, an EDC (Electronic Data Capture)-focused firm that delivers solutions to the clinical research community. MacGarvey worked in an operational and commercial capacity, helping the company to expand its service offerings and launch its services into the U.S. market. Additionally, he has held technology and operational positions at Omnicare, Statwood and PRA International.
MacGarvey expects to see significant growth in the U.S., particularly with FDA pressures on biotech and pharmaceutical companies to provide more in-depth and complex data as they move through all phases of clinical trials. “The market grew by 15% last year and this growth looks set to continue,” he noted. “Much of the growth will be from U.S. companies conducting trials here and overseas. With our ability to deliver services across three continents and our flexibility to adapt to any technology environment, I believe that Quanticate is in a very positive competitive position.”
About Quanticate
Quanticate, with headquarters in Cambridge, MA and London, UK, is the largest global biometrics company with full service clinical trial capabilities. Trusted and respected throughout the industry, Quanticate delivers premium quality clinical trial services, consultancy, highly scalable on-and off-site data management, statistical programming and analysis, and medical writing solutions. Dedicated staff recruitment services are provided through Quanticate People. With resources spanning three continents, Quanticate is renowned for its dedication to clients, world-class service and superior results. In working closely with biotech, pharmaceutical and medical device companies, Quanticate prides itself in being a seamless extension of its customers’ internal teams offering the flexibility to adapt to any technology environment. For more information, visit www.quanticate.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
